Using a new sensitive reverse-phase HPLC assay relying on UV detection at 344 run, the capacity of 18 human liver microsomal samples to support NADPH-dependent, cytochrome P450-mediated oxidation and arachidonic acid-dependent oxidation of the enantiomers of flnans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene (B[a]P-7,8-DHD) was determined. The (-)-7J*,87f-enantiomer, the preferred substrate of cytochrome P450, formed 94% diolepoxide 2 (anti-isomer; 7*,85-oMhydroxy-9S40*-e^xy-7,8,940-tetrahydrobenzo[a]-pyrene) measured as derived alcohols, and the (+)-7S,8S-enantiomer formed 67% diolepoxide 1 (syn-isomer; 7S,SRdihydroxy-9S,10*-epoxy-7,8,9,10-tetrahydroben2o[a]pvrene). Arachidonic acid-supported oxidations gave -70% diolepoxide 2 from each enantiomer. The involvement of different sets of cytochrome P450 isozymes was supported by incubations in the presence of a-naphthoflavone (a-NF) (50 /iM) and correlation studies. -7,8-diol-9,10-epoxides (1). These exist as a pair of diastereomers in which the 7-hydroxyl group is either cis (syn-isomer or diolepoxide 1) or trans (qntiisomer or diolepoxide 2) to the 9,10-epoxide group (2). The formation of two optical enantiomers of each diastereomeric diolepoxide is possible (1). They spontaneously hydrate to stereoisomeric pairs of tetraols by cis and trans addition of water in reactions not catalyzed by epoxide hydrase (3).
Introduction
Tra/w-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene (B[a]P-7,8-DHD*) can undergo oxidative metabolism catalyzed by rodent liver microsomes to form the B[a]P-7,8-diol-9,10-epoxides (1). These exist as a pair of diastereomers in which the 7-hydroxyl group is either cis (syn-isomer or diolepoxide 1) or trans (qntiisomer or diolepoxide 2) to the 9,10-epoxide group (2) . The formation of two optical enantiomers of each diastereomeric diolepoxide is possible (1). They spontaneously hydrate to stereoisomeric pairs of tetraols by cis and trans addition of water in reactions not catalyzed by epoxide hydrase (3) .
The stereochemistry of epoxidation of B[a]P-7,8-DHD is of importance since the different diolepoxide isomers differ in their reactivity toward nucleic acids and in their mutagenicity and carcinogenicity. In this respect, the (-f-)-enantiomer of the ami diolepoxide, derived from (-)-B[a]P-7,8-DHD, has been found to possess greater biological activity in mammalian cells than the other diree stereoisomers of B[a]P-7,8-diol-9,10-epoxide (1,4). Due to this high activity, diolepoxide 2 is now regarded as an ultimate carcinogen derived from benzo[a]pyrene (B[a]P).
There are two possible mechanisms by which the epoxidation of B[a]P-7,8-DHD can take place: oxidation may be mediated by the mixed-function oxidase system involving cytochrome P450 (3, (5) (6) (7) , or may proceed through a peroxyl radical-mediated mechanism (8) . Peroxyl radicals are generated in a variety of biochemical situations and co-oxidation of B[a]P-7,8-DHD by epoxidation at the 9,10-double bond occurs. This diolepoxide formation occurs during microsomal lipid peroxidation in liver microsomes triggered by the addition of ascorbate or NADPH in the presence of ironfJH) and ADP (9) , and in mouse keratinocytes (10) . Enzymatic generation of peroxyl radicals occurs during the lipid hydroperoxide-dependent co-oxygenations of B[a]P-7,8-DHD involving prostaglandin H synthase (8, (10) (11) (12) (13) (14) (15) and lipoxygenases (13, 16, 17) . B[a]P-7,8-DHD epoxidation also occurs during hematin-catalyzed decomposition of fatty acid hydroperoxides (18, 19) and bisulfite peroxidation (20) or autoxidation (21) . In addition the cytochrome P450 enzymes have peroxygenase activity and can oxidize toluene and methylaniline supported by hydroperoxides (22) , can convert lipid hydroperoxides to lipid peroxidation products (23) , and can reductively cleave hydroperoxides in the presence of NADPH (24) .
It has been reported from animal studies that the stereoselectivity of epoxidation of B[a]P-7,8-DHD by peroxyl radicals is distinct from that exhibited by the cytochromes P450. Peroxyl radicals epoxidize (+)-B[a]P-7,8-DHD-mainly to the (-)-enantiomer of the diolepoxide 2 and the cytochromes P450 epoxidize it mainly to the (-l-)-enantiomer of the diolepoxide 1. (-)-B[a]P-7,8-DHD is epoxidized by both pathways to the (-l-)-enantiomer of the diolepoxide 2 (9, 19, 25, 26) .
The aim of the present study was to determine the relative contribution of the NADPH-dependent, cytochrome P450-mediated oxidation and the arachidonic acid-dependent, peroxyl radical-mediated oxidation of the (+)-and (-)-enantiomers of B[a]P-7,8-DHD in human liver microsomes. The stereoselectivities of the reactions and the effects of various additives were also examined.
Materials and methods

Chemicals
The following chemicals were purchased from the NCI Chemical Carcinogen Repository through Chemsyn Science Laboratories, Lexena C.E.Scharping, M.E.McManus and G.M.Hokter 9-triol), 7|3,8a,9/3,10-tetrahydro-7,8,9-trihydroxybenzo{a]pyrene (B[a]P-7, 9/8-triol), a/U7-B[a]P-7,8-diol-9,10-epoxide. B[a]P-7,8-diol-9,10-epoxide and mz/u-dihydro-4,5-dihydroxybenzo[a]pyrene (B[a]P-4,5-DHD).
Biochemicals
NADPH was purchased from Boehringer Mannheim Corp., Sydney, Australia. Butylated hydroxyanisole (BHA), nordfliydroguaiaretic acid (NDGA), a-naphthoflavone (a-NF), arachidonic acid, indomethacin and phenylbulazone were obtained from the Sigma Chemical Company, St Louis, MO, USA. SKF525A was purchased from Smith Kline and French Laboratories, Sydney, Australia. fcir-l.l-Naphthol (Fluka Chemicals, Darmstadt, FRG) and HPLC-grade methanol (Mallinckrodt Speciality Chemicals Co., KY, USA) were obtained from the sources listed. Gestodene (13-ethyl-17/3-hydroxy-18,19-di-nor-17a-pregn»4,15-diene-20-yn-3-one) was a generous gift of Dr H.Kuhl (University of Frankfurt, Germany).
Liver microsomes
Rat liver tissue. Control and phenobarbital-induced rat liver microsomal samples were prepared as described (27) .
Human liver tissue. All the human liver microsomal samples except SV2 were samples from the liver bank held in the Department of Clinical Pharmacology Flinders University, Bedford Park, SA and were prepared by the method previously described (28) . The SV2 liver tissue was obtained from St Vincents Hospital, Sydney. Three of the human liver samples were obtained by liver resection from patients suffering from liver tumour (subjects H12, H13 and SV2). In these cases, an apparently normal part of the tissue was taken. All other samples were removed from organ transplant donors 30-60 min after death (29) . The clinical details of the subjects are shown in Table I . The use of human liver tissue in this study has received the approval of both Hospital and University Human Ethics Committees.
Methods
NADPH-Supported metabolism of(+)-and (-)-B[a]P-7,8-DHD by human liver microsomes.
Metabolic studies were carried out using 1 ml incubations in 0.05 M Tris-HCl buffer, pH 7.4, containing 0.5 mg human liver microsomal protein and 4.5 mM MgCl 2 . Various additives were preincubated with the reaction mixture for 2 min at 37°C, the final concentrations being 2 pM for BHA (added in 4 /d methanol), and 50 pM for o-NF (added in 20 pi acetone). The substrate, either (+)-or (-)-B[a]P-7,8-DHD (20 pM final concentration) was then added in acetone (20 pi) and then NADPH in buffer (0.1 ml, 0.5 mg, final concentration 0.6 mM) was added. After incubation at 37°C in a shaking water bath for 30 min, the reaction was terminated by rapid cooling in ice and 1.0 M phosphate buffer, pH 3.5 (0.1 ml) was added. One hour later, the internal standard (0.25 pg 1,1 '-ftu-naphthol) in ethyl acetate (1.0 ml) was added to the cold mixtures, which were then vortexed for 20 s. After further extraction with ethyl acetate (2 X 1 ml), the pooled organic layers were evaporated undeT vacuum at 30°C, and the residue was transferred to an autosampler vial using ethyl acetate (2 x 0.1 ml). The ethyl acetate was evaporated under nitrogen, the residue was dissolved in dimethylformamide (DMF) (30 pi) and an aliquot (20 pi) was analysed by HPLC. Blanks contained no NADPH. All manipulations were performed under yellow light to minimize the decomposition of the compounds.
Inhibition studies using gestodene. Gestodene inhibition of (+)-and (-)-B[a]P-7,8-DHD oxidation was determined using three human liver microsomal samples (H5, Hll and H12) in the. presence and absence of a-NF. Reaction mixtures were prepared as described. Gestodene (100 pM), in 20 pi of acetone and NADPH (0.5 mg, in 50 pi buffer) were added and preincubated for 30 min in a shaking water bath at 37°C. BHA (2 pM), in 4 pi acetone and a-NF (50 pM) in 10 pi acetone were then added and the mixtures were preincubated for a further 2 min before the substrate (20 pM) was added in 10 pi acetone, followed by a further 0.5 mg NADPH in buffer (50 pi, total 1.2 mM). The oxidation of (+j-and (-)-B[a]P-7,8-DHD was then assayed as described above.
Arachidonic odd-supported metabolism cf(+}-and (-)-B{a]P-7,8-DHD by human liver microsomes. Incubations (1.0 ml) in 0.05 M Tris-HCl buffer, pH 7.4, contained human liver microsomal protein (0.5 mg) and various additives, which were preincubated for 2 min at 37°C. The concentrations of these additives in the final incubation were BHA (2 pM, added in 4 pi methanol), NDGA (100 pM, added in 100 pi Tris-HCl buffer), indomethacin (100 pM, added in 30pi acetone) and phenylbutazone (100 pM, added in 30 pi acetone). Substrate, (+)-or (-)-B[a]P-7,8-DHD (20 pmol in 20 pi acetone) was added to the cold incubation mixture, and the reaction was started by the addition of arachidonic acid (0.1 pmol in 5 pi Tris-HCl) and transferred to a shaking water bath at 37°C. After 30 min the reaction was terminated by rapid cooling on ice and 1 M phosphate buffer, pH 3.5 (0.1 ml), was added. After voitexing, the incubation mixtures were allowed by stand in ice for 1 h, and worked up as described above for NADPH-supported metabolism. Blanks contained no arachidonic acid.
Quantisation of the B[a]P-7,8-DHD metabolites
Preparation of standard curves. Seven standard solutions of the four B[a]P-7,8,9,10-tetraols and the two B[a]P-7,8,9-triols derived from the ami-and jwi-isomers of B[a]P-7,8-diol-9,10-epoxide by hydrolysis and reduction were prepared in DMF so that 50 pi contained 7.5, 15, 30, 60, 120, 180 and 240 ng of each compound respectively. In separate test tubes, an aliquot (50 pi) of each standard solution was added to liver microsomal protein (0.5 mg) prepared from phenobarbitone-pretreated rats in 0.05 Tris-HCl buffer, pH 7.4 (1 ml). The test tubes were vortexed for 10 s and 1 M phosphate buffer, pH 3.5 (0.1 ml), was then added to each. A period of further vortexing (10 s) followed by 1 h in ice was allowed before the internal standard l,l'-^u-naphthol (0.25 pg) in ethyl acetate (1 ml) was added and each was further extracted with ethyl acetate as described for NADPH-supported metabolism. HPCL of the extracted standards allowed the peak area ratios of each anatyte to that of the internal standard to be calculated. These values were plotted against the metabolite amount (ng) and linear regression equations for the six compounds were obtained. In every case the value of the correlation coefficient exceeded 0.999. Recoveries were determined for the four tetraols across the whole concentration range by direct injection onto the HPLC; a mean of 60% was obtained. 
Results and discussion
Metabolic assay methods
Assays for B[a]P-7,8-DHD metabolism have generally relied on the use of radioactive substrates and subsequent radiochemical determination of metabolic products (3, 15, 17) or changes in UV absorbance due to consumption of substrate (48) . The current study employed a reverse-phase HPLC of compounds derived from the diastereoisomers of B[a]P-7,8-diol-9,10-epoxide by hydrolysis and NADPH-mediated reduction and an internal standard. Products were B[a]P-7,10/8,9-tetraol, B[a]P-7/8,9,10-tetraol and B[a]P-7/8,9-triol from the a/i/i-diolepoxide diastereoisomer, and B[a]P-7,9,10/8-tetraol, B[a]P-7,9/8,10-tetraol and B[a]P-7,9/8-triol from the .ry/i-diolepoxide diastereoisomer. Quantitation was carried out using l,l'-bisnaphthol as the internal standard, and peak area ratios were determined after incubation mixtures were adjusted to pH 3.5 with phosphate buffer and allowed to stand for a sufficient period of time to guarantee complete hydrolysis. Using the antidiolepoxide, which is the isomer of lesser reactivity towards hydrolysis under neutral conditions (30) , experiments involving addition of the epoxide to incubation buffer at pH 7.4 containing 0.5 mg/ml rat liver microsomal protein followed by immediate extraction gave incomplete recoveries of the diolepoxide (as hydrolysis products) in the organic extracts. When solutions of the a/tfj-diolepoxide in the presence of protein were adjusted from pH 7.4 to pH 3.5 by addition of phosphate buffer, and allowed to stand for periods of up to 1 h, hydrolysis increased. After 15 min the reaction was 85% complete and by 1 h total hydrolysis had occurred. Therefore a 1 h hydrolysis period at pH 3.5 was included in the assay. Problems with the analysis of these diolepoxides have been recognized by others. Thus during hematin-catalyzed oxidation of B[a]P-7,8-DHD, initiated by unsaturated fatty acid hydroperoxides, poor recovery of radioactivity was noted (18) , and during methanol/water gradient HPLC of the diolepoxides themselves (3) or of prostaglandin synthase co-oxidation products 10-0-methylated B[a]P-tetraols were formed (31). The limit of detection of the assay was -2 ng for each analyte, which under the conditions of the incubation and HPLC translates to ~ 1 pmol metabolites/mg protein/min. Incubations designed to determine NADPH-supported cytochrome P450-catalyzed oxidation of B[a]P-7,8-DHD were effected in the presence of 2 /*M BHA. Preliminary experiments with human liver microsomes in the absence of BHA gave high blank values (no NADPH), which made measurements of the NADPH-supported reaction unreliable. Using rat liver microsomal protein to effect the NADPH-supported oxidation of B[a]P-7,8-DHD even higher blanks were obtained, but in the presence of 1, 2, 5 and 10 /tM BHA blanks were very substantially reduced. The chosen concentration of 2 /iM gave minimal inhibition of the rat liver microsomal catalysed oxidation. The oxidation of B[a]P-7,8-DHD seen even in unincubated blanks in the absence of BHA is probably mediated by peroxides both present in the microsomal preparation and formed during incubations (8, 23, 24) , in part perhaps by lipoxygenase (13, 16, 17, 47 ) (see later discussion). The very substantial reduction of these blank values in the presence of a low concentration of BHA supports this proposal. Data collected in the Tables show the capacity of 18 samples of human liver microsomes to catalyze the NADPH-supported oxidation (Tables II and HI) , and arachidonic acid-supported oxidation (Tables IV and V) of the enantiomers of B[a]P-7,8-DHD to B[a]P-diolepoxides 1 and 2. The total metabolic capacity and the relative amounts of the two diolepoxides derived from the sums of their hydrolysis and reduction products are given. The proportion of this found as triols ranged from 4 to 30%. Protein-bound products from the diolepoxides could not be determined but in other work the proportion was low (-5%) (14) or moderate (>30%) (3). Tables II and HI ) and the product ratios were characteristic for each enantiomer of the dihydrodiol. The ( + )-enantiomer was metabolized to a mean 67% diolepoxide 1, while the (-)-enantiomer was converted to a mean 94% diolepoxide 2. With cytochromes P450LM 2 an d P450LM, purified from rabbit liver, showed a much greater activity towards these B[a]P derivatives than LM 2 (5,25), and LM4 preferentially metabolizes the (-)-isomer. In a similar fashion, the (-)-isomer was converted predominantly to diolepoxide 2. Thakker et al. (1) reported the high stereoselectivity in the formation of diolepoxide 2 relative to diolepoxide 1 from the 7.r?,8^?-enantiomer by liver microsomes from 3-methylcholanthrene-pretreated rats and with purified cytochrome P448 (IA1). Microsomes from control and phenobarbitone-treated rats metabolized (+)-and (-)-B[a]P-7,8-DHD with less stereoselectivity. These differences in stereoselectivity in the metabolism of the B[a]P-7,8-dihydrodiols reflect the differences in the proportion of various cytochrome P450s present in liver microsomes from control, MC-induced and phenobarbitone-induced rats.
NADPH-dependent metabolism qf(+)-and (-)-B[a]P-7,8-DHD
In the present work, differences between individuals in the proportions of diolepoxide 1 and diolepoxide 2 derived metabolites formed from (+)-and (-)-B[a]P-7,8-DHD also probably reflect differences in the content of particular cytochrome P450s in the liver microsomes. Drug pretreatment, smoking habit and genetic factors have been shown to influence the expression of specific P450s in human liver. a-NF has been reported to be capable of stimulating some P450-mediated reactions in human liver microsomes and inhibiting others (4, 6, (33) (34) (35) (36) . In the present work, 50 /*M a-NF increased the metabolism of ( + )-B[a]P-7,8-DHD by a mean 2.27 fold (P < 0.001) ( Figure 2D ; Table II ). This stimulatory effect occurred in all samples; however, the extent of stimulation varied from 1.26-fold to 4.24-fold. The a-NF caused a mean 4.3-fold increase in the amounts of diolepoxide 2 hydrolysis products formed, while the amounts of diolepoxide 1-derived products remained virtually unchanged. (There was a mean 1.3-fold change.) This translated as a decreased proportion of diolepoxide 1 products and an increased proportion of tetraols derived from diolepoxide 2.
Metabolism of B(a]P-7,M)HD enantkuners
The effect of 50 /iM a-NF on the metabolism of (-)-B[a]P-7,8-DHD was to decrease it by a mean 0.86-fold (P < 0.05) (Table HI) . This inhibitory effect was not observed in all samples, and six of the 18 samples showed increases in metabolism. a-NF generally increased the amounts of diolepoxide 1 metabolites formed and decreased the amounts of diolepoxide 2 metabolites formed, resulting in the changed proportions shown in Table ID .
The liver samples used were those described in McManus et al. (29) , and the relative P450IA2 and P450IIIA3/4 contents of these samples were available. Those results were used to determine the correlation of the relative content of these P450 isozymes with the rates of metabolism of (+)-and (-) 8-DHD after stimulation by a-NF. This conclusion was also supported by the observation that the human liver microsomal samples obtained from patients known to be receiving dexamethasone, a synthetic glucocorticoid, as a medication (patients H5, H7 and H15) were among those that showed the highest fold increases in metabolism of (+)-and (-)-B[a]P-7,8-DHD after stimulation by a-NF. The samples H5, H7 and H15 gave 4.24-, 3.41-and 2.22-fold increases in the metabolism of the (+)-enantiomer, and 2.25-, 1.08-and 1.06-fold increases in the metabolism of the (-)-enantiomer respectively when a-NF was included in the incubation mixture. The specific activities of these three samples towards both the (+)-and (-)-enantiomers of B[a]P-7,8-DHD in the absence of a-NF were not significantly higher than the 15 other human liver microsomal samples. Since dexamethasone is an inducer of the cytochrome P450IIIA enzymes (37), these results support the correlation studies which point to an involvement of the P450IIIA3/4 enzymes in the metabolism of the (+)-and (-)-enantiomers of B[a]P-7,8-DHD only after stimulation by a-NF, but not in the absence of a-NF.
In all human liver microsomes examined, P450IA2 is the dominant P450IA protein present (29) . However, due to the difficulty associated with separating P450IA1 and IA2 proteins on SDS-PAGE, the presence on P450IA1 mRNA in 11 of the 23 livers tested in our laboratory (38) , and the fact that the polyclonal anti-rabbit P450IA2 IgG used in these studies recognizes both P450IA proteins, the possibility of the P450IA2 band containing P450IA1 protein cannot be totally discounted. In the present study in the absence of a-NF, the metabolism (pmol metabolites formed/mg protein/min) of the (-)-enantiomer of B[a]P-7,8-DHD correlated positively with P450IA2 protein content (r = 0.72, r 2 = 0.518) of human liver microsomes. No •Specific enzyme activities are expressed as pmol metabolites/ing protein/min using 100 pM arachidonic acid and a substrate concentration of 20 fiM. b Additives were BHA (2 ftM), NDGA (100 pM), phenylbutazone (100 /iM) or indomethacin (100 /iM).
•These data have been corrected for endogenous oxidation in the presence of the additive and absence of added arachidonic acid. (29) observed that the ability of expressed human P450IA1 and P450IA2 to N-hydroxylate AAF (2-acetylaminofluorene) was strongly inhibited by a-NF. In addition, a-NF at low concentrations also inhibited the capacity of the P450IA1 and P450IA2 proteins to activate IQ (2-amino-3-methylimidazo[4,5-/|quinoline) and PhIP (2-amino-l-methyl-6-phenyUmidazo [4,5-Z>] pyridine) in the Ames test (29) , and at high concentrations stimulated the ability of P450HIA proteins to metabolize these compounds to mutagens (34) . Shimada et al. (6) Correlation studies supported this conclusion. In the present work a-NF stimulated the metabolism of (+)-B[a]P-7,8-DHD and inhibited the metabolism of (-)-B[a]P-7,8-DHD. According to the correlation studies, cytochrome P450HIA3/4 was important in the metabolism of both enantiomers of the substrate only after stimulation by a-NF. This conclusion was drawn by Shimada et al. (6) , but contrary to the present findings, they found no correlation of either B[a]P-7,8-DHD isomer umu gene responses with the activities catalyzed by P450p A (P450IA2). We examined the effect of gestodene, an ethynylic steroid with progestational properties and which was shown to be an effective inactivator of the cytochromes P450IIIA (40) (41) (42) (43) . Using three microsomal preparations (H5, Hll and H12), preincubation of the microsomes with NADPH and gestodene in experiments conducted in the absence of a-NF had only a relatively small inhibitory effect on the metabolism of (+)-and (-)-B[a]P-
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7,8-DHD (-22% decrease) compared to experiments in which a-NF was added to the preincubation. Here metabolism of (-)-B[a]P-7,8-DHD was inhibited by 78.3 ± 3.0% while that of(+)-B[a]P-7,8-DHD was inhibited by 66.3 ± 9.1% (n = 3). These results further show the major role of the ITJA3/4 proteins in the metabolism of both enantiomers of the substrate after a-NF pretreatment, while illustrating the minor role these enzymes play when there is no activation by a-NF. The extent of the inhibition by gestodene was not dependent on the prior activation of the IIIA protein by a-NF since results were independent of the order of preincubation.
In animal liver microsomes, 2-diethylaminoethyl 2,3-diphenylvalerate (SKF525A) has been shown to be a potent inhibitor of the cytochrome P450 system (44, 45) . In the present work, further confirmation of the involvement of the cytochrome P450 enzymes in the NADPH-dependent metabolism of (+)-and (-)-B[a]P-7,8-DHD is provided through the significant inhibition effected by 500 /*M SKF525A. In the presence of 2 /xM BHA, the metabolism of the (-l-)-enantiomer was inhibited by a mean 35% and the metabolism of the (-)-enantiomer was inhibited by a mean 42 %. Similar extents of inhibition were observed in the absence of BHA. The presence of SKF525A in the incubation mixtures generally had little effect on the proportions of diolepoxide 1-and diolepoxide 2-derived products produced (data not shown). Tables IV and V (Table HI) . In the presence of both arachidonic acid and either BHA, NDGA or phenylbutazone, the activities were reduced to <27% of the conversion in the presence of added arachidonic acid only. The (+)-enantiomer of the substrate gave a mean 73% diolepoxide 2-derived products and the (-)-enantiomer afforded a mean 69% diolepoxide 2-derived metabolites. This stereochemistry is in agreement with that of the peroxyl radical-mediated oxidations (8-10,16-18, 21,26) .
Arachidonic acid-supported conversion of (+)-and (-)-B[a]P-7,8-DHD to diolepoxides
There was no significant difference between the mean extent of arachidonic acid-supported oxidation of the (+)-and (-)-enantiomers of B[a]P-7,8-DHD but there was a wide variation in activities within the human liver microsomal samples. Sample SV2, for example, had a very low activity towards both of these substrates, whereas sample H8 showed a higher than average activity. The SV2 liver sample was obtained by liver resection from a patient (a smoker) with a liver tumor, while H8 liver sample was obtained from a renal transplant donor who was also a smoker.
Confirmation of the free radical nature of the arachidonic aciddependent metabolism of (+)-and (-)-B[a]P-7,8-DHD is provided by the substantial inhibition effected by the antioxidants BHA and NDGA. Prostaglandin synthase co-oxidations are inhibited at the hydroperoxidase step by both BHA and NDGA, but this enzyme was not thought to be involved in these samples in a peroxide radical-mediated process because 100 /iM indomethacin, an inhibitor of cyclooxygenase, did not inhibit the metabolism consistently and in many samples increases occurred. The ratio of diolepoxide 2 to diolepoxide 1 is also inconsistent with a major role for prostaglandin synthase oxidation of the B[a]P-7,8-DHDs because the latter enzyme forms little or no diolepoxide 1 (11, 15) .
Alternatively, upoxygenase may be responsible for this activity. Such an involvement in the arachidonic acid-dependent metabolism of (+)-and (-)-B[a]P-7,8-DHD was consistent with the substantial inhibition by 100 fiM NDGA, a Upoxygenase inhibitor (46) as well as an antioxidant. This proposal is supported by observations by Nemato and Takayama (47) who suggested a role for Upoxygenase in the arachidonic acid-dependent activation of B[a]P to protein-binding species with cytosolic and microsomal fractions from rat liver and lung. The observation that phenylbutazone (100 /*M) inhibited the arachidonic acidsupported metabolism of (+)-and (-)-B[a]P-7,8-DHD generally by > 80% appears to discount this pathway in the present work. If Upoxygenase was involved in the metabolism of these compounds an increase in 7,8-dihydrodiol oxidation would have been seen. Reed et al. (48) found that 100 /iM phenylbutazone markedly stimulated the prostaglandin H synthase-catalyzed oxidations of B[a]P-7,8-DHD, and we found that phenylbutazone (100 /tM) markedly augmented the metabolism of (±)-B[a]P-7,8-DHD by soyabean Upoxygenase (data not shown). The augmentation was higher in the absence of added arachidonic acid.
It appears more likely that oxidation of the enantiomers of B[a]P-7,8-DHD occurs by a mechanism in which the peroxidase activity of cytochrome P45O is involved together with lipid peroxides or hydroperoxide present in the microsomal preparations (9, 18, 24) . In such a mechanism phenylbutazone may act as an alternative substrate to the B[a]P-7,8-DHD and undergo preferential oxidation (48) . However, a contribution from active peroxyl radicals produced by Upoxygenase via arachidonic acid cannot be completely discounted.
The ability of these microsomal preparations to convert B[a]P-7,8-DHD enantiomers to diolepoxides via hydroperoxidemediated or oxene-mediated reactions represent significant bioactivation pathways. The formation of the (-l-)-enantiomer of diolepoxide 2 from B[a]P-7/?,8/?-DHD is a particularly significant pathway since this 7,8-diol-9,10-epoxide is highly tumorigenic in rodents in contrast to its enantiomer and the two diolepoxide 1 enantiomers (1,4). This ultimate rodent carcinogen is virtually the only detectable product of the NADPH-supported human hepatic microsomal metabolism of (-)-B[a]P-7,8-DHD and is the major product of the pathway supported by arachidonic acid. While rodent hepatic metabolism of B[a]P is known to favour the formation of the (-)-7fl,8J?-dihydrodiol, the stereoselectivity of polycyclic aromatic hydrocarbon oxidation catalysed by human cytochromes P450 has not to our knowledge been reported. If pathways similar to those of rodents are followed, the oxidation of the (+)-75,8S-dihydrodiol is unimportant toxicologically, firstly because it is either not formed in liver or formed in exceptionally low amounts compared to the (-)-isomer, and secondly, although its metabolic products are genotoxic, they have minimal activity in rodent bioassays for tumorigens (1). The use of the presentiy described assay showing the stereoselectivity of metabolism of B[a]P-7,8-DHD is therefore more pertinent than conversion to products which mutate the umu, his G and his D genes of Salmonella typhimurium (1,6,7).
